NCT06918886Not yet recruiting
Comparison of Liver Health in Psoriatic Arthritis Patients Using Anti-TNF or Anti-IL17 Treatments
Evaluation of Liver Fibrosis and Hepatic Steatosis Using FIB-4 Score and Ultrasonography in Psoriatic Arthritis Patients Treated With TNF or IL-17 Inhibitors: A Retrospective Controlled Study
Source: ClinicalTrials.gov · Last updated 9 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Psoriatic arthritis (PsA) is an inflammatory joint disease that can also affect the liver. Some medications used to treat PsA, such as biological agents (TNF-alpha inhibitors and IL-17 inhibitors), may influence liver health over the long term. This retrospective study aims to evaluate the presence and progression of liver fibrosis (scarring) and hepatic steatosis (fatty liver) in PsA patients treated with TNF-alpha inhibitors or IL-17 inhibitors. The study includes PsA patients who have used biological medications continuously for at least 2 years. Patients' liver health will be assessed using non-invasive tests such as liver ultrasonography and validated biochemical scoring systems (FIB-4, APRI). The findings will be compared with PsA patients treated only with methotrexate (MTX), a commonly used medication known to affect liver health. This study will help understand whether biological therapies (TNF or IL-17 inhibitors) have a positive or negative impact on liver health compared to traditional treatments (MTX) in patients with psoriatic arthritis.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 90 (estimated)
- First submitted
- 17 Mar 2025
- Start date
- 10 Apr 2025
- Primary completion date
- 30 Apr 2025
- Lead sponsor
- Bezmialem Vakif University
- Diseases
- Psoriasis, Psoriatic arthritis
- NCT number
- NCT06918886
What you commit to
- Study type: Observational
- Planned participants: 90
- From 10 Apr 2025 to the primary completion date, 30 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant use of other hepatotoxic drugs apart from MTX
Other illness
- History of any other chronic liver disease (e.g., viral hepatitis, autoimmune hepatitis)
Other
- Significant alcohol consumption (\>20 g/day women, \>30 g/day men)
- Unwillingness or inability to comply with study assessments
Who the study is looking for
- Age 18 to 65 years
- Diagnosed with psoriatic arthritis (PsA) according to standard classification criteria
- Receiving biologic therapy (anti-TNF or anti-IL-17) or MTX monotherapy for ≥2 years
- Able to provide historical data (medical records) on liver ultrasound and laboratory parameters
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bezmialem Vakif University Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.